Interesting article, thanks for posting.
I'm not sure I would classify all the drugs listed as competitors to MPL though:
ABBVCLS-7262 may be, I am not across it enough to say for sure either way. It is also targeting TPD43 but the mechanism appears to be different so could be complementary.
I would be interested to hear from anyone who has a better grasp of how this drug compares to MPL?
AP-01 appears to be targeting the SOD1 variant (MPL is not, Patients at risk of or known to carry a SOD1 mutation or VCP mutation were excluded from the MPL trial)
CNMAU-8: I believe this has a different target (ie not autophagy) so may be complementary - I would be keen to hear more from anyone who has a good grasp of this?
RAPA-501 This is an open-label, non-randomized, multi-center intermediate size expanded access clinical trial of single-agent RAPA-501 cells in patients with high-risk ALS who are not eligible for other ALS clinical trials.
- Forums
- ASX - By Stock
- NUZ
- PharmAust media thread
PharmAust media thread, page-314
-
- There are more pages in this discussion • 4 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add NUZ (ASX) to my watchlist
(20min delay)
|
|||||
Last
22.5¢ |
Change
-0.015(6.25%) |
Mkt cap ! $109.4M |
Open | High | Low | Value | Volume |
24.0¢ | 24.0¢ | 22.5¢ | $133.9K | 573.8K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
3 | 303213 | 22.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
23.0¢ | 57592 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
2 | 258769 | 0.225 |
9 | 351041 | 0.220 |
2 | 26627 | 0.215 |
1 | 10000 | 0.210 |
3 | 101948 | 0.205 |
Price($) | Vol. | No. |
---|---|---|
0.230 | 42000 | 1 |
0.240 | 20367 | 1 |
0.245 | 339236 | 4 |
0.250 | 306054 | 5 |
0.255 | 8641 | 1 |
Last trade - 15.46pm 18/10/2024 (20 minute delay) ? |
Featured News
NUZ (ASX) Chart |